Omnicell Inc (NASDAQ:OMCL) Institutional Investors Sentiment Up in Q4 2016

July 18, 2017 - By Clifton Ray

 Omnicell Inc (NASDAQ:OMCL) Institutional Investors Sentiment  Up in  Q4 2016

Sentiment for Omnicell Inc (NASDAQ:OMCL)

Omnicell Inc (NASDAQ:OMCL) institutional sentiment increased to 1.32 in Q4 2016. Its up 0.44, from 0.88 in 2016Q3. The ratio increased, as 99 active investment managers increased or started new stock positions, while 75 cut down and sold their positions in Omnicell Inc. The active investment managers in our partner’s database now own: 34.04 million shares, up from 33.74 million shares in 2016Q3. Also, the number of active investment managers holding Omnicell Inc in their top 10 stock positions decreased from 3 to 2 for a decrease of 1. Sold All: 14 Reduced: 61 Increased: 73 New Position: 26.

Omnicell, Inc. provides automation and business analytics software solutions for patient-centric medication and supply management across the entire healthcare continuum, from the acute care hospital setting to post-acute skilled nursing and long-term care facilities to the home. The company has market cap of $1.61 billion. It operates through two divisions: Automation and Analytics, and Medication Adherence. It currently has negative earnings. The Automation and Analytics segment is engaged in the design, manufacturing, selling and servicing of medication and supply dispensing systems, pharmacy inventory management systems and related software.

The stock increased 0.47% or $0.2 during the last trading session, reaching $43.1. About shares traded. Omnicell, Inc. (NASDAQ:OMCL) has risen 33.21% since July 18, 2016 and is uptrending. It has outperformed by 16.51% the S&P500.

Kopp Investment Advisors Llc holds 3.22% of its portfolio in Omnicell, Inc. for 89,847 shares. Conestoga Capital Advisors Llc owns 1.34 million shares or 3.03% of their US portfolio. Moreover, Lyon Street Capital Llc has 2.26% invested in the company for 130,509 shares. The Illinois-based Oak Ridge Investments Llc has invested 1.92% in the stock. Paradigm Capital Management Inc Ny, a New York-based fund reported 448,300 shares.#img1#

Since January 1, 0001, it had 0 buys, and 9 sales for $5.11 million activity.

Omnicell, Inc. (NASDAQ:OMCL) Ratings Coverage

Ratings analysis reveals 100% of Omnicell’s analysts are positive. Out of 8 Wall Street analysts rating Omnicell, 8 give it “Buy”, 0 “Sell” rating, while 0 recommend “Hold”. The lowest target is $33.0 while the high is $55. The stock’s average target of $42.29 is -1.88% below today’s ($43.1) share price. OMCL was included in 12 notes of analysts from July 31, 2015. The firm has “Buy” rating by Cantor Fitzgerald given on Monday, June 12. The rating was initiated by Dougherty & Company with “Buy” on Thursday, January 19. Benchmark maintained Omnicell, Inc. (NASDAQ:OMCL) on Tuesday, December 6 with “Buy” rating. The firm earned “Outperform” rating on Friday, July 31 by Oppenheimer. The firm has “Buy” rating by Topeka Capital Markets given on Monday, November 16. The firm has “Buy” rating by Sidoti given on Monday, September 28. Topeka Capital Markets maintained the stock with “Buy” rating in Friday, July 31 report. The stock of Omnicell, Inc. (NASDAQ:OMCL) has “Buy” rating given on Thursday, January 7 by Benchmark. FBR Capital maintained the stock with “Buy” rating in Thursday, September 3 report. On Friday, October 30 the stock rating was maintained by FBR Capital with “Outperform”.

Another recent and important Omnicell, Inc. (NASDAQ:OMCL) news was published by Nasdaq.com which published an article titled: “Omnicell (OMCL) Rides on Acquisitions Amid Tough Competition” on July 05, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: